skip to Main Content
Pfizer Bets On Medical Cannabis With $6.7 Billion Acquisition

Pfizer is to enter the medical cannabis industry betting on a promising cannabinoid-based bowel disease treatment.

Last week, American multinational pharmaceutical and biotechnology corporation Pfizer signed an agreement with the clinical-stage company Arena Pharmaceuticals for a total equity value of around $6.7 billion.

Under the agreement terms, Pfizer acquires all shares for $100 per share in an all-cash transaction. Moreover, the press release reads that the proposed transaction will be subject to customary closing conditions, including receipt of regulatory approvals and approval by Arena’s stockholders.

Arena Pharmaceuticals is a biotech company with one pipeline dedicated to cannabinoid-type therapeutics. The core of its cannabis operation consists of Olorinab (APD371), an investigational, oral, full agonist of the cannabinoid type 2 receptor (CB2), which aims to treat patients with diseases affecting the stomach and intestine. As Arena’s website states, Olorinab is an investigational drug and is not currently approved for use by any health authority.

Arena’s team is developing this cannabinoid-based drug with an initial focus on visceral pain associated with gastrointestinal disorders. Arena’s website reads that this compound, through its selectivity for CB2 versus CB1, is under investigation for pain relief without psychoactive adverse effects. [Read more at Forbes]

This Post Has 0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Stories

Guns or marijuana, but not both

While marijuana became legal for adults to purchase in Montana on New Year’s Day, a key federal agency has confirmed a fact underreported in coverage of the state’s new marijuana program: It remains illegal under federal law for individuals to simultaneously possess marijuana or marijuana products and firearms, and penalties for violating that law are…

As Oklahoma’s medical marijuana industry booms, regulators struggle to keep up

Row by row, Oklahoma Bureau of Narcotics and Dangerous Drugs agents and Garvin County deputies cut down 2,500 marijuana plants and loaded them in a dump truck for destruction during an April 2021 raid near Pauls Valley. The grow operation had a Oklahoma Medical Marijuana Authority license, but had not obtained an additional permit from…

European Cannabis Round-Up; GW Pharma’s Cannabis Pipeline, Irish CBD In Court, UK Medical Cannabis Price Row, Italian Referendum, Poland And Malta

GW Pharmaceuticals has released further details of its cannabis development pipeline. With Epidiolex approved in the US last year it is also expecting approval for Sativex where two phase 3 trials are ongoing. Work is also underway on the use of Sativex in spinal cord injury, post-traumatic stress disorder and other forms of spasticity. Further…

ICYMI: Adding Marijuana to a NIST Handbook

by Hilary Bricken, Principle at Harris Bricken Not many people get excited about revisions and updates to the very dry National Institute of Standards and Technology  (“NIST”) handbooks. For example, the NIST 44 Handbook contains the “Specifications, Tolerances, and Other Technical Requirements for Weighing and Measuring Devices.” The handbooks are adopted every year at the…

More Categories

Back To Top
×Close search
Search